Tirofiban hydrochloride - Generic Drug Details

What are the generic drug sources for tirofiban hydrochloride and what is the scope of patent protection?

Tirofiban hydrochloride is the generic ingredient in two branded drugs marketed by Medicure, Eugia Pharma, Gland, and Nexus, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for tirofiban hydrochloride. Five suppliers are listed for this compound.

Summary for tirofiban hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	5
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	68
Patent Applications:	2,211
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tirofiban hydrochloride
What excipients (inactive ingredients) are in tirofiban hydrochloride?	tirofiban hydrochloride excipients list
DailyMed Link:	tirofiban hydrochloride at DailyMed

Recent Clinical Trials for tirofiban hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beijing Anzhen Hospital	PHASE4
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	PHASE3
General Hospital of Shenyang Military Region	PHASE3

See all tirofiban hydrochloride clinical trials

Pharmacology for tirofiban hydrochloride

Drug Class	Platelet Aggregation Inhibitor
Physiological Effect	Decreased Platelet Aggregation

Anatomical Therapeutic Chemical (ATC) Classes for tirofiban hydrochloride

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for TIROFIBAN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AGGRASTAT	Injection	tirofiban hydrochloride	5 mg/100 mL	020913	1	2019-08-29
AGGRASTAT	Injection	tirofiban hydrochloride	12.5 mg/250 mL	020913	1	2018-10-03

US Patents and Regulatory Information for tirofiban hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gland	TIROFIBAN HYDROCHLORIDE	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	206888-001	Apr 8, 2021	AP	RX	No	No
Medicure	AGGRASTAT	tirofiban hydrochloride	INJECTABLE;INJECTION	020912-001	May 14, 1998		DISCN	No	No
Nexus	TIROFIBAN HYDROCHLORIDE	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	213947-001	Feb 7, 2023	AP	RX	No	No
Nexus	TIROFIBAN HYDROCHLORIDE	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	213947-002	Jul 24, 2023	AP	RX	No	No

Expired US Patents for tirofiban hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913-002	May 17, 2002	5,292,756
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913-002	May 17, 2002	6,136,794
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913-001	May 14, 1998	6,770,660
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913-001	May 14, 1998	5,292,756

Market Dynamics and Financial Trajectory for Tirofiban Hydrochloride

Last updated: March 13, 2026

What is the current market landscape for Tirofiban Hydrochloride?

Tirofiban Hydrochloride is an intravenous antiplatelet agent approved for acute coronary syndrome (ACS) management. It functions as a reversible glycoprotein IIb/IIIa receptor antagonist, preventing platelet aggregation. Its predominant application is in percutaneous coronary intervention (PCI).

The drug faces competition from alternatives like abciximab and eptifibatide, but its simple synthesis and shorter half-life provide favorable pharmacokinetics.

Market Size and Forecast

• Estimated global market value in 2023: approximately $250 million.
• Compound Annual Growth Rate (CAGR): 6.5% projected from 2023 to 2030.
• Key regions include North America (55% market share), Europe (25%), Asia-Pacific (15%), and remaining territories (5%).

The growth is driven by increasing adoption in hospitals for PCI procedures, expanding indications in thrombolytic therapy, and rising incidences of cardiovascular diseases.

Market Drivers

1. Rising Cardiovascular Disease (CVD) Incidence: The WHO reports over 19 million annual deaths due to CVD worldwide [1].
2. Advancements in Cardiac Interventions: Innovations in PCI techniques increase demand for antiplatelet drugs.
3. Regulatory Approvals and Label Expansions: Efforts to extend indications or gain approvals in emerging markets boost revenue streams.
4. Hospital Procurement Policies: Governments and private institutions prioritize effective antiplatelet agents, favoring drugs with proven safety profiles.

Market Challenges

1. Generic Competition: Several authorized generics and biosimilars entered markets, exerting downward pressure on prices.
2. Stringent Regulatory Environment: Approvals and post-market surveillance add complexity.
3. Pricing Pressure: Payer negotiations and cost-containment strategies limit revenue escalation.
4. Limited Market Exclusivity: Patent expirations have been observed in key regions, reducing competitive barriers.

What are the financial projections for Tirofiban Hydrochloride?

Revenue Trends

Year	Estimated Global Revenue ($ million)	Assumed Growth Rate	Notable Factors
2023	250	—	Base Year
2024	267	6.8%	Market expansion, new approvals
2025	284	6.3%	Increased adoption, competitive pricing
2026	303	6.7%	Introducing biosimilars, emerging markets
2027	323	6.6%	Patent expirations, price reductions

Key Revenue Influencers

• Market Penetration: Growth depends on hospital adoption rates and physician prescribing habits.
• Pricing Dynamics: Price reductions due to biosimilar competition impact margins.
• Manufacturing Costs: Economies of scale and process improvements can enhance profitability.
• Regulatory Events: Approvals or restrictions affect supply and demand.

Cost Structure Overview

• Research & Development (R&D): Limited, given established pharmacology.
• Manufacturing Expenses: Include raw materials, quality assurance, and facilities.
• Marketing & Distribution: Focused on hospital procurement channels.
• Regulatory Compliance: Ongoing costs for post-market surveillance.

Investment and Licensing Opportunities

Licensing deals with generic and biosimilar manufacturers are common, providing upfront payments and royalties. Companies also prioritize pipeline diversification through combination therapies or new indications.

How do regulatory policies impact the market?

Regulatory agencies, including the FDA and EMA, approve and monitor the drug's safety and efficacy. Recent updates include:

• FDA Priority Review (2021): Expedited approval process for new indications.
• EMA Variations (2022): Expanded label in European markets for specific patient subgroups.
• China NMPA Approvals (2023): Entry into emerging markets through local licenses.

Patent landscapes are shifting rapidly. Tirofiban Hydrochloride patents expired or approaching expiration in multiple jurisdictions, opening margins for biosimilars within 3-5 years.

What is the competitive landscape?

Company	Strengths	Market Position
Pfizer (off-label use)	Established sales channels, R&D focus	Market leader in certain regions
Teva Pharmaceutical	Biosimilar development, licensed production	Emerging competitor
Sandoz (Novartis)	Biosimilar pipelines, global reach	Increasing presence
Local generic manufacturers	Cost advantages, market access	Regional dominance

Biosimilar entries are anticipated as patent protections lapse, especially in North America and Europe.

Conclusion

Tirofiban Hydrochloride maintains a steady growth trajectory primarily driven by the expansion of PCI and ACS treatments. Market dynamics are influenced by competitive pricing, biosimilar entries, regulatory environments, and regional healthcare policies. Revenue growth remains moderate, with forecasts suggesting continued expansion into emerging markets and new indications, countered by pricing pressures and patent expirations.

---

Key Takeaways

• Global market expected to reach $350 million by 2030, with a CAGR of 6.5%.
• Market growth fueled by rising CVD prevalence and expanding PCI procedures.
• Patent expirations open opportunities for biosimilar competitors, affecting pricing.
• Regulatory approvals and regional healthcare policies heavily influence market dynamics.
• Revenue prospects hinge on hospital adoption, pricing strategies, and competitive innovations.

---

FAQs

Q1. How does biosimilar competition affect Tirofiban Hydrochloride’s revenue?
Biosimilar entries typically reduce drug prices, lower margins, and diminish market share for original formulations. As patents expire, biosimilars gain traction, pressuring pricing and profitability.

Q2. Are there any new indications that could expand Tirofiban Hydrochloride’s market?
Current focus remains on ACS and PCI. Expansion into thrombolytic therapy or acute ischemic stroke remains investigational, with no approved new indications as of 2023.

Q3. Which regions are emerging as significant markets for Tirofiban Hydrochloride?
Asia-Pacific, Latin America, and Eastern Europe are growing markets due to increasing cardiovascular disease rates and expanding healthcare infrastructure.

Q4. What is the impact of regulatory shifts on the drug’s market?
Expedited approvals, new label expansions, and streamlined registration processes facilitate market access but can also intensify competition if biosimilars are approved quicker.

Q5. How do hospital procurement policies influence Tirofiban Hydrochloride sales?
Hospitals favor drugs with proven safety, efficacy, and cost-effectiveness. Tendering processes and formulary inclusion heavily influence market share and sales volume.

---

References

[1] World Health Organization. (2021). Cardiovascular diseases. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases